Novo Holdings invests £53.5 million into Oxford Biomedica
May 30, 2019Business Services, Sales and Marketing Novo Holdings, Novo Nordisk, Oxford BioMedica, Shares, cell and gene therapy, lentivirus
Novo Holdings has agreed to buy 10.1% of shares in British firm Oxford Biomedica for £53.5 million. Novo will buy …
Janssen presents strong Phase 3 showing for Darzalex in multiple myeloma subgroup
May 30, 2019Research and Development Janssen, darzalex, pharma
Janssen has lifted the curtain on new Phase 3 data for Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (Rd), …
Oklahoma prosecutors say J&J used ‘brainwashing campaign’ to boost opioid sales
May 30, 2019Research and Development J&J, JJ, opioid crisis, opioids, pharma, public health
Oklahoma state prosecutors have accused Johnson & Johnson of engaging in a “cynical, deceitful, multibillion-dollar brainwashing campaign” to boost sales …
Pharma firms paid Italian doctor to promote opioid drugs
May 29, 2019Research and Development Italy, Mundipharma, Purdue, opioids, pharma
Opioid drugmakers paid an Italian pain doctor to promote opioid painkillers as a treatment for chronic pain, Italian prosecutors say. …
FDA first as agency expands label on Celgene’s Revlimid in previously treated follicular or marginal zone lymphoma
May 29, 2019Research and Development, Sales and Marketing Cancer, Celgene, FDA, Revlimid, lymphoma, pharma
Celgene has revealed that the FDA has expanded its authorised indications of Revlimid (lenalidomide) to include combination with a rituximab …
UK government refuses to sign up to WHO pricing transparency resolution
May 29, 2019Research and Development WHA, WHO, access, health UK, pharma, pricing
The UK government has refused to sign up to a global resolution on transparency in drug pricing which urges governments …
FDA approves Theranica’s smartphone-controlled electroceutical device for migraine
May 29, 2019Research and Development FDA, Nerivio Migra, Theranica, migraine, pharma
Biomedical tech company Theranica has secured FDA approval for Nerivio Migra, its wearable, smartphone-controlled electroceutical device, for the acute treatment …
Manchester emerges as genomics research hub
May 29, 2019Research and Development Diagnostics, Manchester, UK, genomics, pharma
Manchester, UK is emerging as a major hub for genomics research, according to a new firm set up in collaboration …
Living with Scimitar syndrome
May 28, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Scimitar syndrome, patient experience, pharma
Katy Baker has lived her entire life with the rare congenital heart defect Scimitar syndrome. She reflects on the system …
Pfizer’s Lyrica fails at Phase 3 in treating primary generalised tonic-clonic (PGTC) seizures
May 28, 2019Manufacturing and Production, Research and Development, Sales and Marketing Lyrica, Pfizer, epilepsy, pharma, trial failure
Pfizer has unveiled new Phase 3 data on the effectiveness of Lyrica (pregabalin) in the adjunctive treatment of primary generalised …
FDA delays Newron Pharmaceuticals’ trial into schizophrenia drug evenamide
May 28, 2019Manufacturing and Production Newron Pharma, evenamide, pharma, schizophrenia
Newron Pharmaceuticals has halted a clinical trial of its schizophrenia drug evenamide after the FDA raised concerns about reports of …
Pharma sector is a bigger polluter than the automotive industry
May 28, 2019Manufacturing and Production CO2, Green, eco-firendly, emissions, pharma, pollution
The pharmaceutical industry is a bigger polluter than the automotive sector, according to a study from researchers at McMaster University. …
FDA approves first therapy PIK3CA-mutated HR+/HER2- advanced breast cancer
May 28, 2019Manufacturing and Production, Sales and Marketing Cancer, FDA, Novartis, Piqray, breast cancer, fulvestrant, pharma
Novartis’ Piqray (alpelisib) has secured approval from the FDA in combination with AstraZeneca’s Faslodex (fulvestrant) for the treatment of hormone …
Novartis’ $2.15m SMA drug Zolgensma becomes most expensive FDA-approved therapy
May 28, 2019Manufacturing and Production AveXis, FDA, Zolgensma, access, drugs, pricing, sma
The FDA has approved Novartis subsidiary AveXis’ $2.15 million gene therapy Zolgensma for children with spinal muscular atrophy (SMA). The …
FDA approves new tests for chlamydia and gonorrhoea
May 24, 2019Medical Communications STIs, chlamydia, gonorrhoea, public health FDA
The FDA has approved two new tests which make it easier to diagnose common STIs. The approval comes after a …
Top Ten most popular articles on Pharmafile.com this week
May 24, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Gilead, J&J, JJ, MSD, Sandoz, pharma, top ten
On the day that UK Prime Minister Theresa May announces her resignation, we look back on the week’s biggest stories …
China approves GSK’s shingles vaccine Shingrix
May 24, 2019Medical Communications, Sales and Marketing China, GSK, Shingrix, pharma, shingles
GSK’s shingles vaccine has secured approval in China, the company said, after the National Medical Products Administration (NMPA) authorised the …
Mumps cases triple in England
May 24, 2019Medical Communications MMR, UK, Vaccine, health, public health
Public Health England has urged patients to ensure that they have received the MMR vaccine after the number of cases …
GSK to reintroduce bonuses for sales reps
May 24, 2019Medical Communications GSK, US, oncology, pharma, sales, sales reps, scandal
British multinational GlaxoSmithKline said on Thursday that it would reintroduce performance-based bonuses for some sales reps in some countries. The …
Drugmakers colluded to drive up price of anti-nausea drug by 700%
May 23, 2019Business Services, Medical Communications Business, NHS, collusion, competition, pharma
Four pharmaceutical firms have been accused of illegally colluding to restrict the supply of anti-nausea medication Prochlorperazine after the price …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
